
STRIDES ARCOLAB ANNOUNCES US FDA APPROVAL FOR ITS 'BRAZILIAN STERILE PENEMS FACILITY'

- *Products approvals and commercialization expected in second half of 2012*
 - *Products licensed to partners worldwide*
-

February 24, 2012, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for its 'Brazilian Sterile Penems facility'.



This state-of-the-art facility manufactures sterile dry powder injectables of Penems. The plant has already been approved by other international regulatory agencies like MHRA and ANVISA and with this approval the Company is in a position to commercialize products worldwide in the second half of Year 2012.

The approval is also the first US FDA approval for an international facility of Strides. The approval and commercialization of the products which are already licensed to partners worldwide are expected in the second half of Year 2012.

Commenting on the occasion, Venkat Iyer, CEO, Agila Specialties, said, "This approval for our Brazilian Sterile Penems manufacturing facility in the niche domain is another milestone in positioning Agila as a leading global injectable player".

About Penems

Carbapenems are a class of β -lactam antibiotics with a broad spectrum of antibacterial activity and one of the last resorts for many bacterial infections. They have a structure that renders them highly resistant to most β -lactamases. The global market size for Penems is approximately USD 2 Billion.



About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 13 manufacturing facilities across 5 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick
Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)	Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
	Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in

